Griseofulvin (Grisovin)
Griseofulvin
Glaxosmithkline South Africa (Pty) Limited
Registration
- Applicant
- Glaxosmithkline South Africa (Pty) Limited
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Grisovin 125 MG TABLET GRISEOFULVIN A 125 MG | 125 MG | A0502 | Old Medicine | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Griseofulvin
- except when intended for topical application to the epidermis, nares and external ear.
Consolidated Schedules 06 July 2026, line 6548
S2: Griseofulvin
- when intended for application to the skin, nares and external ear.
Consolidated Schedules 06 July 2026, line 2065
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(2S,5'R)-7-Chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
Drag to rotate. Structure from PubChem CID 441140.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.